Posted by Michael Wonder on 22 Dec 2022
US FDA extends review of Pfizer’s new drug application for Paxlovid
20 December 2022 - Pfizer oral treatment remains available to eligible US patients under emergency use authorisation as a critical tool in the fight against COVID-19.
Pfizer announced today that the US FDA has extended the review period for the new drug application for its COVID-19 oral treatment, Paxlovid (nirmatrelvir tablets and ritonavir tablets).
